Research & Development

The ALARIC clinical trial represents a monumental leap forward in the treatment of light chain amyloidosis, marking the first time that European researchers have utilized Chimeric Antigen Receptor (CAR) T-cell therapy for this specific patient population. Led by a collaborative team from University

Ivan Kairatov is a leading biopharma expert with a deep specialization in the intersection of artificial intelligence and immunology. With an extensive background in research and development, he has spent years navigating the complexities of how technology can accelerate drug discovery and vaccine

The overwhelming biological disparity between male and female glioblastoma outcomes has long suggested that sex hormones play a foundational role in the aggressive progression of this lethal brain cancer. Glioblastoma multiforme remains one of the most formidable challenges in modern neuro-oncology

The biological reality of why a patient’s metabolic health dictates the survival path of pancreatic cancer has remained a persistent shadow in modern oncology. While clinicians have noted for years that obesity and type 2 diabetes correlate with worse outcomes, the actual genetic machinery

In the intricate world of pediatric neurology, the sudden onset of life-threatening seizures in a previously healthy infant remains one of the most harrowing experiences for families and clinicians alike. Dravet syndrome, a severe form of epilepsy that typically surfaces during the first twelve

When a child is diagnosed with a serious condition like Wilms tumor, parents often face the agonizing decision of whether to seek treatment at a massive urban teaching hospital or a smaller local specialist center. This dilemma stems from the assumption that higher patient volumes and larger